AFBI vs APGE
AFBI: Affinity Bancshares is a community-focused bank holding company providing commercial and retail banking services to individuals and businesses. APGE: Apogee Therapeutics is a clinical-stage biotechnology firm developing advanced biologic therapies for inflammatory and immunology diseases, currently pending acquisition by AbbVie.
Side-by-side fundamentals
| Metric | AFBI | APGE | Edge |
|---|---|---|---|
| Price as of 2026-09-09 close | $23.00 | $135.07 | |
| Market cap as of 2026-09-03 | $140M | $10.2B | |
| P/E as of 2026-09-03 | 16.70 | n/a | |
| PEG as of 2026-09-03 | 0.32 | -4.90 | APGE lower |
| ROE FY2025, SEC XBRL | +6.6% | -28.3% | AFBI higher |
| ROA FY2025, SEC XBRL | +0.9% | -27.3% | AFBI higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +25.7% | n/a | |
| Dividend yield as of 2026-09-03 | +6.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.17 | 1.16 | |
| 1-year return as of 2026-09-09 close | +17.0% | +263.8% | APGE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.